Excent Capital Announces Swap-Free Trading on All U.S. Stocks and Indices

Brasília, Brazil – November 06, 2025 – (SeaPRwire) – Excent Capital, an international multi-asset regulated brokerage, announced today the expansion of its swap-free trading conditions to include all U.S. stocks and major equity indices. This guarantees zero overnight financing fees for both long and short positions, giving traders more flexibility to hold trades without any extra daily costs. What This Means for Traders Swap fees, also known as overnight charges, are applied when positions remain open across market sessions. By removing these charges on U.S. equities and index CFDs, Excent Capital helps traders: Reduce ongoing holding costs; Manage medium and long-term positions comfortably; Navigate periods of higher volatility with fewer cost constraints; Position trades prior to earnings announcements. This change supports both active traders and long-term strategists who want flexibility without the pressure of overnight charges. Zero-Slippage Execution Across All Assets In addition to the swap-free update, Excent Capital reaffirms its zero-slippage execution model across all tradable assets under normal market conditions. This means that when the market is stable and liquid, orders are executed at the exact price requested, with no positive or negative deviation. The price you see is the price you get. If markets are experiencing extreme volatility, major news releases, or high liquidity gaps, traders may encounter price adjustments. However, in normal trading conditions, execution remains strictly zero slippage. For traders, this provides greater precision when opening or closing positions, supporting more predictable outcomes in risk management. Traders can rely on their planned levels without unexpected deviations, while benefiting from clear and consistent pricing with instant execution. “Our clients tell us that what they value most is precision. The combination of swap-free assets and zero-slippage execution lets traders stay fully focused on their strategy.” said Marcelo Lima, Business Development Manager at Excent Capital. This update reflects Excent Capital’s continued effort to provide institutional-grade trading conditions to both retail and professional clients, with a focus on accessibility, transparent risk management, and operational efficiency. About Excent Capital Excent Capital is a multi-regulated global execution-only brokerage offering access to FX, indices, commodities, equities, ETFs and digital assets. The company maintains operational presence across multiple regions, including Latin America, North America, Europe and Africa, allowing it to support traders and partners with local communication and market understanding. The company is regulated by the Financial Services Authority (FSA) of Seychelles and partners with Equals Money, an FCA-regulated UK financial institution, to provide international payments and multi-currency account infrastructure. Excent Capital delivers institutional-grade trading solutions such as MAM and Copy Trading for professional money managers, financial advisors, portfolio managers and traders. Contact Information Brand: Excent CapitalContact: Ryccielli Ongaratto, Marketing ManagerEmail: support@excent.capitalWebsite: https://excent.capital/

SeaPRwire推出虛擬新聞編輯助手,提升編輯效率

Hong Kong - 2025年11月3日 - SeaPRwire,領先的新聞傳播平臺,推出了一款創新的虛擬新聞編輯助手,該系統由SeaPRwire與合作夥伴Asia Presswire (https:/asiapresswire.com)共同開發。該人工智能驅動的系統旨在輔助新聞編輯進行內容編輯和校對,提高編輯工作流程的效率和準確性。 隨著對高質量、無錯誤內容的需求不斷增長,新聞機構和媒體開始越來越依賴技術來簡化其編輯流程。傳統的編輯和校對方法往往耗時且容易出現人為錯誤,尤其是在新聞內容量日益增加的情況下。SeaPRwire的虛擬新聞編輯助手通過提供一個自動化解決方案,利用人工智慧幫助編輯快速而準確地優化新聞內容,從而解決了這一挑戰。 "我們推出的虛擬新聞編輯助手對於希望提高編輯速度和精准度的新聞機構來說,是一次具有革命性的變革,"SeaPRwire客戶支持總監Lucy Clark表示。"通過使用人工智慧技術,系統可以高效地審查內容,糾正語法和句法錯誤,並提供增強新聞文章清晰度和流暢性的建議。它為新聞編輯提供了一個強大的工具,確保內容不僅準確,而且精緻和專業。" 該系統通過分析新聞文章的結構和語言,識別潛在問題,例如拼寫和語法錯誤、語氣不一致或表達不自然。然後,它提供修正和改進的建議,允許編輯快速進行更改,而不妥協工作品質。這在節奏緊張、內容量大的環境中尤為重要。 "隨著新聞機構在緊迫的截止日期下需生產高質量內容的壓力不斷增加,我們的虛擬新聞編輯助手提供了急需的支持,"Clark補充道。"該人工智能系統不僅幫助編輯捕捉他們可能忽視的錯誤,還提升了內容的可讀性和專業性,這對於維護新聞機構的聲譽至關重要。" 通過推出這一先進的工具,SeaPRwire旨在幫助新聞機構、媒體和公關專業人士提高編輯效率,同時保持高標準的品質和準確性。虛擬新聞編輯助手預計將減少手動校對和編輯的時間,讓新聞編輯能夠更多地專注於內容創作和策略。 虛擬新聞編輯助手的推出是SeaPRwire在為不斷發展的媒體環境提供創新解決方案方面邁出的重要一步。通過自動化耗時的編輯任務,該系統幫助新聞機構在要求速度與品質並重的行業中保持競爭力。 SeaPRwire的這一新系統,借助Asia Presswire先進的人工智慧技術,現已向多個行業和地區的用戶開放,提供了一種智能高效的解決方案,以改善編輯工作流程並製作高質量的新聞內容。 關於Asia Presswire   Asia Presswire (https:/asiapresswire.com) 是一家新聞稿發佈服務公司,為全球公關公司、代理機構、組織和企業提供定制化解決方案。他們專注於提供定制化的新聞稿分發服務,包括通過電子郵件直接發送新聞稿給報紙、雜誌和廣播媒體編輯。其廣泛的網路覆蓋172個國家,連接超過230,000個媒體管道以及360萬個自媒體平臺。Asia Presswire支持超過46種語言,包括英語、中文、法語、德語和日語,確保在多語言區域內實現有效溝通。其服務旨在提升品牌的線上可見性和聲譽,有效地與目標受眾建立聯繫。 關於SeaPRwire   SeaPRwire是亞洲領先的媒體傳播管理平臺,旨在賦能公關和傳播專業人士。其品牌洞察計畫通過將客戶與80,000多名記者、編輯、雜誌和線上媒體平臺連接,簡化了傳播管理,同時還與3億多關鍵意見領袖(KOL)粉絲網路對接。借助AI技術,SeaPRwire幫助用戶識別相關媒體和KOL,個性化推介內容,並衡量傳播效果。SeaPRwire在包括日本、中國、韓國、香港、新加坡、越南、泰國、馬來西亞、印尼和菲律賓等地區運營,有效提升品牌認知並教育受眾。 媒體聯繫 Brand: SeaPRwire Contact: Media team Email: cs@seaprwire.com Website: https://seaprwire.com

SeaPRwire Launches Virtual News Editor Assistant to Enhance Editorial Efficiency

Hong Kong – November 03, 2025 – SeaPRwire, a leading Public Relations Communication Platform, has launched an innovative Virtual News Editor Assistant, developed in collaboration with its partner Asia Presswire (https:/asiapresswire.com). This AI-powered system is designed to assist news editors with content editing and proofreading, enhancing both the efficiency and accuracy of editorial workflows. As the demand for high-quality, error-free content grows, news organizations and media outlets are increasingly relying on technology to streamline their editorial processes. Traditional methods of editing and proofreading can be time-consuming and prone to human error, especially with the ever-increasing volume of news content being produced. SeaPRwire’s Virtual News Editor Assistant addresses this challenge by offering an automated solution that leverages artificial intelligence to assist editors in refining news content quickly and accurately. “The launch of our Virtual News Editor Assistant is a game-changer for newsrooms looking to improve both speed and precision in their editorial processes,” said Lucy Clark, Customer Support Director at SeaPRwire. “By using AI technology, the system can efficiently review content, correct grammar and syntax errors, and provide suggestions to enhance the clarity and flow of news articles. It offers news editors a powerful tool to ensure their content is not only accurate but also polished and professional.” The system works by analyzing the structure and language of news articles, identifying potential issues such as spelling and grammatical mistakes, inconsistencies in tone, or awkward phrasing. It then provides suggestions for corrections and improvements, allowing editors to make changes quickly without compromising the quality of their work. This is especially valuable in fast-paced environments where deadlines are tight and the volume of content is high. “With the increasing pressure on newsrooms to produce high-quality content under tight deadlines, our Virtual News Editor Assistant provides much-needed support,” Clark added. “The AI-powered system not only helps editors catch mistakes they may have missed but also enhances the overall readability and professionalism of the content, which is crucial for maintaining the reputation of news organizations.” By offering this cutting-edge tool, SeaPRwire aims to help newsrooms, media outlets, and PR professionals improve their editorial efficiency while maintaining high standards of quality and accuracy. The Virtual News Editor Assistant is expected to reduce the time spent on manual proofreading and editing, allowing news editors to focus more on content creation and strategy. The introduction of the Virtual News Editor Assistant is a significant step in SeaPRwire’s ongoing efforts to provide innovative solutions for the evolving media landscape. By automating time-consuming editorial tasks, this system helps news organizations stay competitive in an industry that demands both speed and quality. SeaPRwire’s new system, powered by Asia Presswire’s advanced AI technology, is now available to users across various industries and regions, offering a smart and efficient solution for improving editorial workflows and producing high-quality news content. About Asia Presswire Asia Presswire (https:/asiapresswire.com) is a press release distribution service that provides tailored solutions for public relations firms, agencies, organizations, and corporations worldwide. They specialize in delivering customized press release distribution, including direct-to-editor email delivery to targeted media editors at newspapers, magazines, and broadcast outlets. Their extensive network spans 172 countries, connecting with over 230,000 media outlets and 3.6 million self-media platforms. Supporting over 46 languages, including English, Chinese, French, German, and Japanese, Asia Presswire ensures effective communication across diverse linguistic regions. Their services are designed to enhance brands’ online visibility and reputation, enabling effective connection with target audiences. About SeaPRwire SeaPRwire is a leading earned media communications management platform in Asia, designed to empower PR and communications professionals. Its Branding-Insight Program streamlines communication management by connecting clients with a network of over 80,000 journalists, editors, magazines, and online media outlets, along with 300 million followers of key opinion leaders (KOLs). Leveraging AI-driven technology, SeaPRwire enables users to identify relevant media and KOLs, personalize pitches, and measure the impact of their communications efforts. Operating across regions including Japan, China, Korea, Hong Kong, Singapore, Vietnam, Thailand, Malaysia, Indonesia, and the Philippines, SeaPRwire enhances brand awareness and educates audiences effectively. Media Contact Brand: SeaPRwire Contact: Media team Email: cs@seaprwire.com Website: https://seaprwire.com

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

SHENZHEN, Oct 30, 2025 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC). MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China. If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector. On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China. About AD Indication MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry 2. Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Decent Cybersecurity Highlights Slovakia’s Tech Leadership at the EU–NZ Business Summit

Auckland, New Zealand – October 30, 2025 – (SeaPRwire) – At the inaugural European Union – New Zealand Business Summit, Decent Cybersecurity represented Europe’s growing strength in digital and defence technologies. The company’s Founder and CEO, Matej Michalko, joined industry leaders to discuss innovation partnerships, cybersecurity resilience, and post-quantum readiness across trans-Pacific markets. The event gathered over 400 participants from business, technology, and research communities, underscoring a shared commitment to building secure and sustainable digital infrastructure between Europe and New Zealand. Hosted by Hon Todd McClay, New Zealand’s Minister for Trade & Investment, in partnership with Team Europe (the Ambassadors of the EU and its Member States), the Summit celebrated the strong growth of trans-Pacific cooperation. Since the EU–NZ Free Trade Agreement entered into force in 2024, two-way trade has already risen by NZ $2 billion, reaching NZ $21.6 billion in 2025. The event was officially opened by Prime Minister Christopher Luxon, who described the EU as “an innovation partner” and emphasised the shared values and strategic alignment between Europe and New Zealand in advancing trade, defence, and technology. A Platform for Global Partnerships and Digital Innovation Commissioner Šefčovič, a native of Slovakia, delivered a keynote address outlining Europe’s vision for resilient supply chains, strategic autonomy, and secure digital transition. Later in the day, the “Quickfire with Central and Eastern Europe” session showcased innovation leaders from across the region. Representing European Union and its member country Slovakia, Matej Michalko presented on the country’s growing role in post-quantum cybersecurity, AI for defence systems, and trusted blockchain infrastructure — areas where Decent Cybersecurity is establishing Europe-wide leadership. “It was an honour to represent European Union and Slovakia alongside Commissioner Šefčovič and to demonstrate how our country is contributing to Europe’s digital and defence sovereignty,” said Matej Michalko, CEO of Decent Cybersecurity. “The EU–New Zealand partnership opens new doors for innovation, technology exchange, and secure infrastructure development that transcend continents.” Shared Vision for Innovation and Security The Summit agenda featured strategic panels on clean tech, AI, bioeconomy, and aerospace & defence, with global leaders from Airbus, Rocket Lab, OHB, and Maersk. It culminated with a joint address by Commissioner Šefčovič and Minister McClay, setting out a shared vision for deeper economic and technological integration between Europe and New Zealand — an effort strongly endorsed by Prime Minister Luxon in his opening remarks. For Decent Cybersecurity, participation in this summit reinforces its mission to connect European post-quantum, blockchain and AI-driven innovation with global partners in the Asia-Pacific region — bridging defence, technology, and critical-infrastructure ecosystems. About Decent Cybersecurity Decent Cybersecurity s. r. o. is a European deep-tech company developing post-quantum and blockchain-based cybersecurity solutions for defence and critical infrastructure. Certified by TÜV SÜD (ISO 9001 and ISO 27001) and holding NATO, EU, and national SECRET-level security clearances, the company is a member of European Defence Fund (EDF) projects and a founding member of the Critical Infrastructure Association of Slovak Republic (Asociácia kritickej infraštruktúry SR, AKI SR). Media contact Brand: Decent Cybersecurity Contact: Media team Email: business@decentcybersecurity.eu Website: https://decentcybersecurity.eu 

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Rα Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

SHENZHEN, CHINA – October 30, 2025 – (SeaPRwire) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of CMS on 22 April 2025 for details) together with its subsidiaries, holds co-development rights (except for atopic dermatitis (AD)) and exclusive commercialization rights for the Class 1 innovative drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (“MG-K10” or the “Product”). The New Drug Application (“NDA”) has been accepted by National Medical Products Administration (“NMPA”) on 30 October 2025. The product is intended for the treatment of adult with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. MG-K10 (generic name: Comekibart Injection) is an innovative long-acting anti-IL-4Rα humanized monoclonal antibody that simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. With a longer half-life, the Product enables a four-week dosing frequency (currently marketed anti-IL-4Rα drugs require biweekly dosing), which is expected to improve patient adherence. MG-K10 is expected to become the world’s first long-acting anti-IL-4Rα monoclonal antibody to be launched on the market, and has the potential to become the Best-in-Class (BIC). MG-K10 has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical study in adults with moderate-to-severe AD, meeting the primary research endpoint as designed, and at 52 weeks of treatment with MG-K10, proportion of participants with Investigator Global Assessment (IGA) score of 0 or 1, also with an improvement of ≥2 points from baseline is 76.6%; proportion of participants with ≥75% reduction in Eczema Area and Severity Index (EASI 75) from baseline is 94.3 %; proportion of participants with ≥90% reduction in Eczema Area and Severity Index (EASI 90) from baseline is 79.1 %. Regarding safety, most of the Treatment Emergent Adverse Event (TEAE) were Grade 1-2, with no Adverse Event of Special Interest (AESI) or fatal adverse event occurred. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product has the potential for the treatment of other type 2 inflammatory diseases, such as asthma, prurigo nodularis, seasonal allergic rhinitis, chronic obstructive pulmonary disease, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Among them, asthma, prurigo nodularis and seasonal allergic rhinitis have all entered the phase III clinical trial stage in China. If MG-K10 is approved, it will provide a new, effective, and safe systemic treatment option for 14.5 million patients with moderate-to-severe AD[1]. Furthermore, MG-K10 will generate synergy with Dermavon’s ruxolitinib cream (for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and dermatology-grade skincare products of Heling soothing product series, establishing a comprehensive solution for AD that covers various administration routes (injection, oral, and topical) and addresses multiple needs in “treatment + care”, benefiting a wide range of AD patients. Concurrently, it will further enrich Dermavon’s product portfolio in the field of dermatological treatment and reinforce its leading position in skin health sector. On 24 January 2025, CMS through its subsidiaries entered into a Collaboration Agreement (“Agreement”) with Hunan Mabgeek Biotech Co., LTD and its subsidiaries for MG-K10. In accordance with the Agreement and supplementary agreements, CMS has obtained the co-development rights (excluding AD) and exclusive commercialization rights for the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore; its subsidiary Dermavon has obtained, through its subsidiary, the co-development rights (excluding AD) and exclusive commercialization rights for the Product in the field of dermatological indications in Mainland China. About AD Indication MG-K10’s first indication, AD, is a chronic inflammatory skin disease accompanied by severe itching. It is the most burdensome non-fatal skin disease worldwide and also a chronic disease with a relatively high prevalence and significant disease burden in China. It is estimated that there are over 54 million AD patients in China in 2024. Based on SCORAD scores, the proportion of moderate to severe AD in China was 27%, which means there are over 14.5 million patients[1]. Due to the limitations in efficacy and safety of traditional systemic therapies for AD, moderate to severe AD patients often experience delays in systemic treatment initiation, poor compliance, and suboptimal disease control, leaving a significant unmet need in clinical practice[2]. MG-K10, with its extended dosing interval of once every four weeks, is expected to improve patient adherence and provide a new, effective, and safe systemic treatment option for patients with moderate-to-severe AD. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: China Insights Consultancy. Industry report on global and China Dermatology Treatment and Care Industry Chinese Society of Dermatology, China Dermatologist Association. Clinical pathway for the diagnosis and treatment of moderate to severe atopic dermatitis in China (2023): an expert consensus[J]. Chinese Journal of Dermatology, 2023, 56(11): 1000-1007. DOI: 10.35541/cjd.20230247. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@cms.net.cn Website: https://web.cms.net.cn/en/home/

韓國知名投顧早安資本深耕台灣市場 三年吸引逾10萬名投資會員

以研究導向與教育推廣雙軌並進 助力台灣投資人掌握全球資產動向 台北,2025年10月29日 - (SeaPRwire) - 自2022年正式進軍台灣市場以來,韓國知名投顧機構 早安投資管理(Good Morning Investment Management Co., Ltd,簡稱「早安資本」) 憑藉專業研究團隊、精準市場洞察與系統化投資教育策略,成功吸引超過10萬名投資會員,成為亞洲市場上成長最快速的跨國投資顧問品牌之一。 早安資本以「讓投資更聰明、更有知識」為使命,透過線上學習平台、社群互動及定期研究報告,協助台灣投資人理解全球經濟脈動。自2022年起,公司已陸續推出台灣專屬的投資研究簡報、每週市場觀察,以及「GMIM智投課堂」線上課程系列,內容涵蓋股債平衡、產業趨勢、量化分析與風險管理等主題,廣受本地投資者好評。 早安資本表示,台灣投資人擁有高度市場敏銳度與資訊吸收能力,是亞洲最具活力的投資族群之一。為回饋本地支持,公司積極與台灣多家金融媒體、學術機構及財經社群合作,共同推動投資教育普及化。早安資本研究部指出,未來三年將持續增加中文研究內容比例,推出台股與東協市場的主題性分析報告,協助投資人掌握區域產業變化。 早安資本執行長表示:「我們非常重視台灣市場的長期潛力。早安資本不僅提供專業投顧,更希望成為連結亞洲投資知識的橋樑。通過教育與研究的雙軌推進,我們致力於協助台灣投資人以全球視角進行資產配置。」 除了投資教育與研究推廣外,早安資本也計畫在2026年推出AI投資分析工具,讓投資人能透過即時數據判斷市場風險與機會,提升決策效率。公司預期,未來將在台灣設立專屬顧問團隊,提供更在地化的資產管理與投資策略建議,深化品牌在亞洲市場的長期影響力。 關於早安資本 成立於2015年,總部位於韓國首爾,韓文名為굿모닝투자일임㈜,簡稱GMIM。早安資本是一家專業資產管理與投顧機構,服務範圍涵蓋亞洲主要市場,提供投資策略設計、風險管理及財富顧問服務。公司秉持研究導向、透明經營與國際視野,致力於推動亞洲投資教育與長期價值投資文化。

International Leo Tolstoy Peace Prize 2025 Highlights Central Asian Cooperation

The International Leo Tolstoy Peace Prize Jury announced the 2025 laureates in recognition of outstanding efforts contributing to regional harmony and security in Central Asia. The award honors the signing of the Treaty on the Junction Point of State Borders and the Khujand Declaration of Eternal Friendship in Khujand, Tajikistan, on March 31, 2025 — landmark agreements that strengthen legal frameworks for mutual trust and cross-border collaboration. Established on June 22, 2022, by the Russian Historical Society, the Russian Peace Foundation, and the Russian Military Historical Society, the International Leo Tolstoy Peace Prize Foundation convenes juries including prominent figures from Argentina, Belarus, India, China, Russia, France, South Africa, and Japan. Jury Chairman Valery Gergiev, renowned conductor and artistic director of the Mariinsky Theatre, emphasized the prize’s mission to “advance global understanding and mutual respect.” He noted the growing reach of the peace movement inspired by Russian writer-philosopher Leo Tolstoy, expressing hope that the prize could, like music, “help nations listen and truly hear one another.” The 2025 honor celebrates the joint efforts of: – Sadyr Japarov, Kyrgyz Republic – Emomali Rahmon, Republic of Tajikistan – Shavkat Mirziyoyev, Republic of Uzbekistan Their collaboration has strengthened stability, sustainable growth, and the international profile of Central Asia. The award ceremony date will be announced soon. About the Prize The International Leo Tolstoy Peace Prize is awarded by an international jury established by the founders of the L.N. Tolstoy International Peace Prize Foundation. The jury is composed of distinguished Russian and foreign figures of recognized international standing and moral authority. Candidates for the Prize may include individuals, initiative groups, national and international public foundations, organizations, movements, scientific and research centers, as well as educational institutions. Self-nomination is not permitted; however, nominators are encouraged to publicly discuss the candidates they propose. Rooted in the humanist ideals of Leo Tolstoy, the Prize honors those whose work embodies the pursuit of peace, moral integrity, and shared progress for humanity. Media contact Organization: The International Leo Tolstoy Peace Prize Contact: Media team Email: tolstoypeaceprize@yandex.ru Website: https://tolstoypeaceprize.org

TOHO and Haneda Airport Team Up for Godzilla Global Project Launch

In late December 2025, the world’s largest indoorGodzilla Monument will be unveiled at Haneda Airport Terminal 3 Singapore – October 23, 2025 – (SeaPRwire) – Toho Co., Ltd. (President: Hiroyasu Matsuoka), Japan Airport Terminal Co., Ltd. (President: Kazuhito Tanaka), and the Tokyo International Air Terminal Corporation (President & CEO: Masatoshi Akahori) have joined forces to launch the HANEDA GODZILLA GLOBAL PROJECT, a mega-scale initiative to share immersive Japanese entertainment from Haneda Airport to the world. Godzilla celebrated its 70th anniversary in November 2024, and its ever-expanding franchise only continues to grow. Its latest frontier will be Haneda Airport – Japan’s gateway to the skies – a popular destination for people from both within Japan and abroad, and a hub for Japanese culture and tradition. In December 2025, a colossal Godzilla, measuring approximately 131 feet wide and 20 feet high, will appear in the Departure Lobby on the third floor of Haneda Airport Terminal 3. Only seen here, this staggeringly mega-scale Godzilla will welcome everyone who visits the airport. Rendering of the Godzilla Monument in the Haneda Airport Terminal 3 Departure Lobby Additionally, graphics of legendary kaiju will be displayed above the Information Counter in the Arrival Lobby on the second floor. On the same floor, a statue of Godzilla from the globally acclaimed film, Godzilla Minus One, will also be displayed to welcome everyone who arrives at Haneda Airport. Rendering of Graphics above the Information Counter in the 2F Arrival Lobby Rendering of the Godzilla Minus One statue in the 2F Arrival Lobby Inspired by the theme of Godzilla greeting and bidding farewell to all visitors to Japan, this project delivers an unprecedented airport experience where Godzilla, a Japanese global icon, bridges the beginnings and ends of their journeys through the power of immersive entertainment. “Welcome” upon their arrival, and “See you again” when they depart.   Blending the excitement of travel and Japanese culture, Godzilla will set the stage for a memorable prelude and epilogue to their journeys. Features A world exclusive monument based on the original Godzilla, created solely for the Haneda Airport Terminal 3 Departure Lobby, with commanding presence and scale at approximately 131 feet wide and 20 feet high. Placed along arrival and departure routes, the two Godzilla statues create an uplifting and lasting impression for travelers’ journeys. A memorable experience unique to Haneda Airport as a hub for Japanese culture and tourism. Exhibition Location: Haneda Airport Terminal 3, 3F Departure Lobby and 2F Arrival Lobby Exhibition Period: Scheduled for completion in late December 2025 to late December 2026 Media Inquiry Regarding Godzilla hello@tohoea.com.sg TOHO Entertainment Asia Media Contact for Haneda Airport inquiries tiat-kouhou@tiat.co.jp Public Relations Tokyo International Air Terminal Corporation

Alexander Melnik: Award-Winning Senior Investment Specialist Driving Excellence at VirPoint

London, UK – October 16, 2025 – (SeaPRwire) – In the competitive world of modern investing, few professionals combine technical mastery, risk discipline, and human intuition as effectively as Alexander Melnik, Senior Investment Specialist and Head of the Crypto Desk at VirPoint.com. With more than a decade of financial-market experience, Melnik has become one of VirPoint’s leading portfolio strategists, helping clients across the UK and Europe achieve consistent results through a carefully balanced mix of technology-driven analytics and hands-on market expertise. Born in Luhansk, Ukraine, Alexander Melnik’s path to financial leadership began early. After completing his studies at Schola No. 7 and later earning a degree from the Financial University under the Government of the Russian Federation (2003–2008), he pursued advanced certifications that established his credibility on the global stage: Chartered Financial Analyst (CFA) Chartered Alternative Investment Analyst (CAIA) Financial Risk Manager (FRM) Following his relocation to the United States in 2009, Melnik worked in the banking sector as until 2017. He continued trading independently through 2020, refining a disciplined style that merges institutional precision with entrepreneurial agility. In 2021, he joined VirPoint, bringing his deep understanding of traditional markets and cryptocurrencies to a firm known for blending AI-driven trading tools with expert human insight. Today, Melnik lives in Knightsbridge, London, with his wife Allison Parker and their two sons, David (4) and Josh (2). A family he often credits as his “anchor and reminder that long-term thinking pays the greatest dividends.” Role at VirPoint: Leadership and Client Success As Head of the Crypto Desk and one of VirPoint’s Senior Investment Specialists, Melnik works primarily with Prime-tier and higher clients across the UK and EU. His focus is on portfolio construction, cross-asset diversification, and the integration of blockchain and digital-asset strategies within broader CFD and equity frameworks. Under his guidance, client portfolios recorded average annual returns of 18.2% in 2023, outperforming the VirPoint average of 8.5% reported by Yahoo Finance. Crypto-focused portfolios achieved even stronger results, with selected strategies delivering 24–27% returns amid volatile market conditions. These results underscore the effectiveness of Melnik’s hybrid approach anchored in real-world data, proactive communication, and long-term vision. Investment Philosophy: AI-Enhanced Human Insight Melnik is a vocal advocate for technology-assisted investing, describing himself as “a big fan of innovation when it serves human intelligence not replaces it.” Within VirPoint’s ecosystem, he has helped refine the AI-based tools that monitor market sentiment, volatility, and correlation risk. Clients receive personal guidance on setting up these features through one-on-one Zoom or phone sessions, where Melnik explains each metric and integrates it into their trading strategy. His risk-management philosophy follows two core frameworks used by top institutional desks: The Kelly Criterion Adaptation – optimizing position size relative to the probability of success to maximize long-term portfolio growth while controlling drawdowns. Value-at-Risk (VaR) Discipline – maintaining exposure within statistically defined loss thresholds, ensuring stability even during unexpected volatility. By blending these quantitative techniques with intuition built from years on trading floors, Melnik helps clients capture opportunities while safeguarding capital – what he calls “the art of growing without overreaching.” Recognition and Excellence Award In 2024, Alexander Melnik and his team were honored with the VirPoint Excellence Award for outstanding performance and deep client satisfaction. The prestigious award, now prominently displayed in the firm’s headquarters, serves as a symbol of Melnik’s lasting impact on client trust and results. Beyond the accolade, he is widely respected for his mentorship of new specialists within VirPoint, always emphasizing integrity, patience, and emotional intelligence as pillars of advisory excellence. His mentorship sessions consistently draw ambitious younger traders eager to learn to balance technical rigor with psychological resilience. Melnik also leads advanced internal training sessions focused on modern asset allocation principles, where he promotes his signature strategy of combining traditional investments with digital assets to improve overall portfolio performance. His approach to strategic reallocation within blockchain-linked instruments has helped clients achieve higher percentage returns while maintaining strong risk control, a philosophy that has since been adopted by several VirPoint advisors across the firm. Under his guidance, many junior advisors have doubled their client satisfaction scores and demonstrated marked improvements in portfolio stability across volatile markets. Personal Approach and Guiding Quote For Melnik, education is not a task – it’s a philosophy. He believes clients should understand why they invest, not just where. His trademark line, repeated in countless client meetings, summarizes this mindset: “Education is the king. Don’t ask yourself if this or if that choose this and that. In diversity and knowledge lies real stability.” Looking Ahead: Join the VirPoint Community As VirPoint.com continues to expand its presence across the UK and Europe, the firm is deepening its commitment to client education and empowerment. New investors are invited to join VirPoint’s New Client Program, which includes a complimentary introductory Zoom session led by experienced specialists such as Alexander Melnik. These sessions cover platform navigation, strategy fundamentals, and effective use of VirPoint’s AI tools – giving clients the confidence to trade smarter from the start. Prospective traders can register directly on VirPoint.com to open an account, explore the VirPoint Academy, and access free resources including tutorials, webinars, and market guides. Whether you are new to CFD trading or managing a diverse portfolio, VirPoint offers the tools, education, and expert support to help you take the next step in your financial journey. Media Contact VirPoint Communications TeamEmail: media@virpoint.comWebsite: https://virpoint.com

SeaPRwire推出多平臺新聞發佈系統,提升新聞覆蓋範圍

Hong Kong - 2025年10月15日 - SeaPRwire,領先的新聞傳播平臺,推出了一款創新的多平臺新聞發佈系統,該系統由SeaPRwire與合作夥伴Asia Presswire (https:/asiapresswire.com)共同開發。此新系統使用戶能夠無縫地在多個平臺上發佈新聞,包括社交媒體、新聞網站和自媒體,從而最大化新聞內容的覆蓋範圍和可見度。 隨著數字通訊的不斷發展,企業和組織在有效觸及目標受眾方面面臨著越來越大的挑戰。傳統的新聞發佈方式往往無法覆蓋現代受眾所參與的廣泛平臺。為應對這一問題,SeaPRwire的多平臺新聞發佈系統旨在確保新聞內容能夠跨越多種平臺進行共用。 "我們推出的多平臺新聞發佈系統標誌著在最大化客戶新聞曝光度方面邁出了重要的一步,"SeaPRwire行銷總監Sam Lee表示。"該系統確保新聞能夠跨越多個數字接觸點,到達預定的受眾,從社交媒體到新聞網站,再到自媒體平臺。它為內容發佈提供了無與倫比的靈活性和廣度,在當今快節奏的媒體環境中至關重要。" 該系統旨在簡化新聞傳播過程,使用戶能夠高效地管理並在不同管道上分發內容,無需多個介面或複雜的工作流程。無論是針對主流媒體還是小眾自媒體平臺,系統都能簡化發佈過程,確保用戶能夠接觸到更廣泛、更多樣的受眾。 通過提供統一的跨平臺發佈平臺,SeaPRwire使組織能夠更有效地管理媒體拓展。與社交媒體平臺的集成確保新聞內容不僅能夠被傳統讀者看到,還能被更廣泛的社交媒體社區分享和互動。因此,用戶能夠顯著提升其線上存在感和可見度。 "在不斷擴展的數字媒體環境中,通過多個管道接觸多樣化的受眾比以往任何時候都更為重要,"Lee補充道。"我們的多平臺新聞發佈系統使用戶能夠在沒有傳統複雜性問題的情況下拓展他們的媒體存在感。這是希望優化溝通策略並接觸全球受眾的組織的必備工具。" 這一新系統由Asia Presswire強大的網路支持,向用戶提供接觸各種媒體和自媒體平臺的機會。這確保了新聞稿、公告和新聞內容能夠傳播給全球受眾,進而提升品牌知名度和互動性。 SeaPRwire的多平臺新聞發佈系統現已面向多個地區和行業的用戶開放,為他們提供了高效管理和擴大新聞傳播的工具。通過簡化發佈過程並擴大新聞內容的覆蓋範圍,該系統有望徹底改變組織與受眾的連接方式,並最大化其媒體影響力。 關於Asia Presswire   Asia Presswire (https:/asiapresswire.com)是一家新聞稿發佈服務公司,為全球公關公司、代理機構、組織和企業提供定制化解決方案。他們專注於提供定制化的新聞稿分發服務,包括通過電子郵件直接發送新聞稿給報紙、雜誌和廣播媒體編輯。其廣泛的網路覆蓋172個國家,連接超過230,000個媒體管道以及360萬個自媒體平臺。Asia Presswire支持超過46種語言,包括英語、中文、法語、德語和日語,確保在多語言區域內實現有效溝通。其服務旨在提升品牌的線上可見性和聲譽,有效地與目標受眾建立聯繫。 關於SeaPRwire   SeaPRwire是亞洲領先的媒體傳播管理平臺,旨在賦能公關和傳播專業人士。其品牌洞察計畫通過將客戶與80,000多名記者、編輯、雜誌和線上媒體平臺連接,簡化了傳播管理,同時還與3億多關鍵意見領袖(KOL)粉絲網路對接。借助AI技術,SeaPRwire幫助用戶識別相關媒體和KOL,個性化推介內容,並衡量傳播效果。SeaPRwire在包括日本、中國、韓國、香港、新加坡、越南、泰國、馬來西亞、印尼和菲律賓等地區運營,有效提升品牌認知並教育受眾。 媒體聯繫 Brand: SeaPRwire Contact: Media team Email: cs@seaprwire.com Website: https://seaprwire.com

Canada Backs Advanced Tokenization and Distributed Federated Learning Research with Over $3 Million in Funding

Montréal, Canada – October 16, 2025 – (SeaPRwire) – T-RIZE Group and École de technologie supérieure (ÉTS) are proud to announce that the Industrial Research Chair in Tokenization, established in 2024 under the leadership of Professor Kaiwen Zhang, has secured over CAD $3 million over five years in contributions and funding from major national funds such as Mitacs and the Natural Sciences and Engineering Research Council of Canada (NSERC) through the Mitacs Accelerate – NSERC Alliance Grants program. This highly competitive Canadian funding underscores the strength of a research program already underway since 2024 – one that has consistently delivered transformative results in blockchain sustainability, real-world asset tokenization, and decentralized federated learning. Building Canada’s Resilient Digital Future At the core of this Chair is a patent-pending communication protocol combined with decentralized federated learning frameworks. These innovations are designed to provide infrastructures that are: Resilient: able to withstand disruptions and adapt dynamically to changing conditions Efficient: optimized to reduce costs, latency, and energy consumption at scale Secure: enabling verifiable and trusted exchanges across distributed environments Sovereign: ensuring that Canada retains control over its critical digital systems and data flows Decentralized federated learning enhances tokenization systems by enabling privacy-preserving collaborative intelligence and real-time risk analysis across distributed networks, making infrastructures not only more secure and efficient but also more adaptive to institutional needs. Such capabilities are vital in an increasingly complex world, where robustness, trust, and independence are essential for both national competitiveness and global cooperation. “This recognition from Mitacs, NSERC, and ÉTS affirms our capacity to build sovereign and resilient infrastructures in an era defined by AI. Through Decentralized Machine Learning, T-RIZE ensures that intelligence remains secure, autonomous, and verifiable – the foundation of digital sovereignty in a world where AI power shapes nations.” – Madani Boukalba, CEO, T-RIZE Group Canada’s Vision in Action The over CAD $3 million in funding from Mitacs, a leading innovation organization, and NSERC Alliance is more than financial support – it is recognition that this research is shaping the future of sustainable and sovereign digital infrastructure. By backing proven, high-impact models, Canada is signaling its intent to lead in technologies that matter: efficient networks, scalable intelligent data architectures, and resilient systems aligned with international standards and sustainability goals. Academic and Industrial Leadership Under the guidance of Professor Kaiwen Zhang, one of Canada’s foremost experts in distributed systems, blockchain, and machine learning, the T-RIZE Chair brings together a team of PhD and postdoctoral researchers at ÉTS, working hand in hand with T-RIZE Group. Together, they are turning advanced research into deployable, institutional-grade systems that strengthen Canada’s position as a global leader in innovation. About Mitacs Mitacs places top-tier talent in Canadian firms to support industry-academia collaboration. This helps unlock innovation potential, de-risk R&D for firms, and build lasting academic-industry relationships. Through its national reach and international partnerships, Mitacs enables Canada to develop the next generation of a skilled and innovative workforce. About T-RIZE T-RIZE has the infrastructure to structure and tokenize a wide range of assets – such as real estate, digital bonds, and high-quality carbon credits – into digital structured products enhanced by federated learning for risk analytics. The platform operates across public and privacy-enabled networks, such as the Canton Network. It has the capacity to integrate insurance and digital ratings to make these products collateral-ready, with distribution conducted through regulated broker-dealers. T-RIZE has tokenized over US$100M, with US$1B in signed projects advancing within a US$5B+ pipeline. The RIZE utility token is the access point to its institutional ecosystem. For more information contact:Press Inquiries: press@T-RIZE.ioHead Office: 1155 René-Lévesque West, Suite 2500, Montreal, QC H3B 3X7, CanadaToronto Office: 130 King Street West, Suite 1900, Toronto, ON M5X 1E3, Canada